Literature DB >> 26565934

Burden of illness among patients with fragile X syndrome (FXS): a Medicaid perspective.

Tara Nazareth1, Nanxin Li2, Maryna Marynchenko2, Zhou Zhou2, Pooja Chopra2, James Signorovitch2, Eric Wu2, Saeed Ahmed1, Jessica Marvel1, Rahul Sasane1.   

Abstract

BACKGROUND: Fragile X syndrome (FXS) is an inherited intellectual disability that imposes a substantial clinical and humanistic burden on patients and caregivers. This study aimed to quantify the incremental burden of illness following FXS diagnosis in Medicaid populations.
METHODS: A retrospective matched-cohort study was conducted using FL, NJ, MO, IA, and KS Medicaid claims (1997-2012). Patients with FXS were matched 1:5 to a comparison group without FXS, based on age, gender, state, and continuous Medicaid coverage. Healthcare resource utilization and costs were compared among cohorts over 1 year following first diagnosis.
RESULTS: Overall, 697 patients with FXS were matched to 3485 non-FXS patients. Median age was 12.0 years; 82% were male. Newly diagnosed FXS patients were younger (median age: 7.0 years). During the follow-up, patients with FXS had significantly higher medication use, medical procedure use, medical specialist visits, and associated costs than the non-FXS comparison group. One-fourth of FXS patients filled prescriptions for stimulants, antipsychotics, or anticonvulsants; 25% of patients with FXS had speech and language therapy and 39% had physical therapy (versus 9%, 4% and 8%, respectively, for the comparison group). At least 44% of FXS patients visited a neurologist, cardiologist, otolaryngologist, or gastroenterologist; 92% of patients with FXS had an outpatient visit, 35% had an emergency room visit, and 34% used home services (compared to 31%-32%, 64%, 27%, and 10%, respectively, for the comparison group) (all p < 0.05). Patients with FXS had an incremental annual total healthcare cost of $33,409 (2012$) per person relative to the comparison group, while newly diagnosed FXS patients had incremental total annual healthcare costs of $17,617 (2012$) per person.
CONCLUSIONS: Both established and newly diagnosed FXS were associated with significantly increased use of multiple medications and medical services, and increased healthcare costs. Treatments that could help reduce this disease burden are urgently needed.

Entities:  

Keywords:  Economic cost; Fragile X syndrome; Healthcare resource utilization; Medicaid

Mesh:

Substances:

Year:  2015        PMID: 26565934     DOI: 10.1185/03007995.2015.1119678

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  4 in total

1.  Fragile X Syndrome-Associated Emergency Department Visits in the United States, 2006-2011.

Authors:  Thuy Quynh N Do; Catharine Riley; Pangaja Paramsothy; Lijing Ouyang; Julie Bolen; Scott D Grosse
Journal:  Am J Intellect Dev Disabil       Date:  2020-03

2.  The Cost of Raising Individuals with Fragile X or Chromosome 15 Imprinting Disorders in Australia.

Authors:  Emma K Baker; Sheena Arora; David J Amor; Perrin Date; Meagan Cross; James O'Brien; Chloe Simons; Carolyn Rogers; Stephen Goodall; Jennie Slee; Chris Cahir; David E Godler
Journal:  J Autism Dev Disord       Date:  2021-07-22

Review 3.  How Knowledge Mapping Can Bridge the Communication Gap Between Caregivers and Health Professionals Supporting Individuals With Complex Medical Needs: A Study in Fragile X Syndrome.

Authors:  Karen Kelm; Francois V Bolduc
Journal:  Front Psychiatry       Date:  2021-11-24       Impact factor: 4.157

4.  Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents.

Authors:  Randi Hagerman; Sebastien Jacquemont; Elizabeth Berry-Kravis; Vincent Des Portes; Andrew Stanfield; Barbara Koumaras; Gerd Rosenkranz; Alessandra Murgia; Christian Wolf; George Apostol; Florian von Raison
Journal:  Sci Rep       Date:  2018-11-19       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.